Table 5.
Studies reporting an association of ANXA11 rs1049550 with sarcoidosis disease phenotypes.
| Study | T Allele Frequency | OR, 95% CI, p Value * | ||||
|---|---|---|---|---|---|---|
| Controls | Resolving | Chronic | Resolving vs. Controls | Chronic vs. Controls | Chronic vs. Resolving | |
| Li et al, 2010 [4] | 0.45 (n = 313) | 0.35 (n = 117) | 0.34 (n = 176) | 0.65, 0.48–0.89, 0.007 | 0.62, 0.47–0.81, 5 × 10−4 | 0.95, 0.67–1.34, 0.76 |
| Levin et al. 2013 [6] # | 0.18 (n = 893) | n = 304 | n = 650 | 0.82, 0.64–1.06, 0.13 §,† | 0.79, 0.65–0.95, 0.02 §,† | |
| Morais et al. 2013 [7] | 0.45 (n = 197) | 0.34 (n = 86) | 0.40 (n = 62) | 0.62, 0.43–0.91, 0.01 | 0.83, 0.55–1.25, 0.37 | 1.33, 0.82–2.14, 0.24 |
| Karakaya et al. | 0.41 (n = 363) | 0.32 (n = 142) | 0.26 (n = 113) | 0.66, 0.50–0.89, 0.005 | 0.51, 0.36–0.70, 4 × 10−5 | 0.76, 0.52–1.12, 0.65 |
| Controls | Löfgren’s Syndrome | Non-Löfgren’s Syndrome | Löfgren’s Syndrome vs. Controls | Non-Löfgren’s Syndrome vs. Controls | Non-Löfgren’s Syndrome vs. Löfgren’s Syndrome | |
| Morais, 2013 [7] | 0.45 (n = 197) | 0.36 (n = 55) | 0.32 (n = 145) | 0.70, 0.45–1.08, 0.11 | 0.57, 0.42–0.78, 5 × 10−4 | 0.81, 0.51–1.29, 0.38 |
| Karakaya et al. | 0.41 (n = 363) | 0.33 (n = 149) | 0.26 (n = 113) | 0.69, 0.52–0.92, 0.01 | 0.51, 0.36–0.70, 4 × 10−5 | 0.73, 0.50–1.07, 0.11 |
| Mrazek, 2011 [5] | TT frequency: 0.15 (n = 254) | TT frequency: 0.21 (n = 39) | TT frequency: 0.07 (n = 147) | 0.31, 0.11–0.84, 0.02 † | ||
* Odds ratio (OR), 95% confidence interval (CI), and p-values are calculated from the data provided in the original articles. # Study population: African Americans. For correct presentation, the C and T allele are switched. § The original article states that the additive genetic model was used to estimate the OR, and the OR is adjusted for sex and percent African ancestry. † Original data were not available; values are copied from the original article.